← Leaderboards

Jonathan W Friedberg

University Of Rochester

Google Scholar ↗PubMed ↗ORCID ↗

$9,248,735

Attributed

$9,248,735

Total exposure

8

Grants

7

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $3M · FY2005–25

$5M$3.8M$2.5M$1.3M$0

'05

'06

'07

'08

'09

'10

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$11,473,993 · 9

By mechanism

P50$3,448,770 · 2

R01$3,271,430 · 1

P30$2,976,287 · 3

U10$1,110,957 · 1

K23$653,830 · 1

M01$12,719 · 1

Top collaborators

Most similar at University Of Rochester

Same institution · by research overlap

Others in their field

Top investigators on “Clinical Trials”

Lawrence Corey · Fred Hutchinson Cancer Center$824,102,536
Sonia M Thomas · Research Triangle Institute$700,865,642
David Heimbrook · Leidos Biomedical Research, Inc.$622,583,125
Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,008,718
Bambra Strokes · Ppd Development Lp$526,656,217
Judith S. Currier · University Of California Los Angeles$504,273,077

Research focus

Clinical TrialsMalignant NeoplasmsLymphomaClinical ResearchBaseUniversitiesProgramsS LymphomaResponseEnrollmentMemberNovel TherapeuticsIn VitroSafetyDrug KineticsApoptosisLaboratoriesCell LineSourcePathway InteractionsEpidemiologyMultidisciplinaryCancer CenterNon-Hodgkin&Apos

Grant awards (29)

University of Rochester Wilmot Cancer Institute Support Grant$2,075,744

P30 · FY2025 · CA · contact PI

Developmental Funds$431,200

P30 · FY2025 · CA · contact PI

Leadership, Planning and Evaluation$319,829

P30 · FY2025 · CA · contact PI

Developing a P01 to Address Cognitive Impairment and Treatment Tolerability in Patients with Advanced Cancer$149,514

P30 · FY2025 · CA · contact PI

Vitamin D and Follicular Lymphoma$592,475

R01 · FY2022 · CA · contact PI

Vitamin D and Follicular Lymphoma$611,816

R01 · FY2020 · CA · contact PI

Vitamin D and Follicular Lymphoma$152,888

R01 · FY2020 · CA · contact PI

Vitamin D and Follicular Lymphoma$596,984

R01 · FY2019 · CA · contact PI

Vitamin D and Follicular Lymphoma$615,082

R01 · FY2018 · CA · contact PI

Vitamin D and Follicular Lymphoma$702,185

R01 · FY2017 · CA · contact PI

Southwest Oncology Group$377,652

U10 · FY2013 · CA · contact PI

CC: Clinical Trials Core$390,893

P50 · FY2012 · CA · contact PI

Southwest Oncology Group$377,652

U10 · FY2012 · CA · contact PI

P-3: Potentiating Proteasome Inhibitor Activity in non-Hodgkin's Lymphoma (NHL)$335,176

P50 · FY2012 · CA · contact PI

CC: Clinical Trials Core$369,842

P50 · FY2011 · CA · contact PI

Southwest Oncology Group$355,653

U10 · FY2011 · CA · contact PI

P-3: Potentiating Proteasome Inhibitor Activity in non-Hodgkin's Lymphoma (NHL)$317,399

P50 · FY2011 · CA · contact PI

CC: Clinical Trials Core$388,781

P50 · FY2010 · CA · contact PI

P-3: Potentiating Proteasome Inhibitor Activity in non-Hodgkin's Lymphoma (NHL)$333,949

P50 · FY2010 · CA · contact PI

CC: Clinical Trials Core$436,725

P50 · FY2009 · CA · contact PI

P-3: Potentiating Proteasome Inhibitor Activity in non-Hodgkin's Lymphoma (NHL)$377,441

P50 · FY2009 · CA · contact PI

P- 3: Potentiating Proteasome Inhibitor Activity in NHL$263,148

P50 · FY2008 · CA · contact PI

CC: Clinical Trials Core$235,416

P50 · FY2008 · CA · contact PI

Monoclonal Antibody Therapy for Follicular Lymphoma$130,766

K23 · FY2007 · CA · contact PI

Monoclonal Antibody Therapy for Follicular Lymphoma$130,766

K23 · FY2006 · CA · contact PI

Monoclonal Antibody Therapy for Follicular Lymphoma$130,766

K23 · FY2005 · CA

PHASE 2, OPEN-LABEL STUDY OF 1018 ISS, FOLLOWING RITUXAN TREATMENT$12,719

M01 · FY2005 · RR

Monoclonal Antibody Therapy for Follicular Lymphoma$130,766

K23 · FY2004 · CA

Monoclonal Antibody Therapy for Follicular Lymphoma$130,766

K23 · FY2003 · CA